BT, It BL and 5 LLtype) were includedin this study. Before treatment, using the PCR lechnique, rhe TT, BT, BL and LL types respectively showed 7/31 (22.6Eù, 4/5 (80.0Vo), 1 Iil I ( 100.07o) and 5/5 ( 100.0Eù PCR positive. AII of the paucibacillary and all 6f the multibacillary patients became PCR negative respectively at 9 and 27 months after MDT treatment.
All of the untreated patients were persistent PCR positive until 9 months treatment (month 9) and 11 of those patients remained PCR positive until 12 months treatment.
The number of PCR positive patients were significantly decreased after 12 months treatment compared with the number of PCR positive patients before treatment (Fischer exact test P < 0.05).
Thereafter the number of PCR positive patients gradually decreased until24 months treatment and all of those patients became PCR negative at 27 months after treatment (month 27). In contrast, a rise in the level of antibody after the start of treatment in relapse patients has been observed.l8
In this study no relapse patients were found during treatment.
In conclusion, the PCR and MLPA test described here are suitable methods for monitoring the efficacy of MDT in untreated leprosy patients and these methods were limited for untreated leprosy patients without relapse during treatment.
